Macrophages: important players in primary Sjögren’s syndrome?

References

• Li S, Nikulina K, DeVoss J, et al. Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease. Invest Ophthalmol Vis Sci 2008;49:34-41
   PubMed Web of Science ®Google Scholar
• Zeher M, Adany R, Nagy G, et al. Macrophage containing factor XIII subunit a in salivary glands of patients with Sjogren’s syndrome. J Investig Allergol Clin Immunol 1991;1:261-5
   PubMed Web of Science ®Google Scholar
• Tominaga M, Migita K, Sano H, et al. Expression of cyclooxygenase-1 (COX-1) in labial salivary glands of Sjogren’s syndrome. Clin Exp Immunol 2000;122:459-63
   PubMed Web of Science ®Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren’s syndrome. J Autoimmun 2012;34:400-7
   Web of Science ®Google Scholar
• Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007:56:3977-88
   Google Scholar
• van Blokland SC, Wierenga-Wolf AF, van Helden-Meeuwsen CG, et al. Professional antigen presenting cells in minor salivary glands in Sjogren’s syndrome: potential contribution to the histopathological diagnosis? Lab Invest 2000;80:1935-41
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Sakaguchi N, Watanabe T. Sialoadenitis in experimental graft-versus-host disease. An animal model of Sjogren’s syndrome. Lab Invest 1991;65:710-18
   PubMed Web of Science ®Google Scholar
• Jabs DA, Prendergast RA. Murine models of Sjogren’s syndrome. Immunohistologic analysis of different strains. Invest Ophthalmol Vis Sci 1988;29:1437-43
   PubMed Web of Science ®Google Scholar
• Chen YT, Li S, Nikulina K, et al. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye. Mol Vis 2009;15:563-76
   PubMed Web of Science ®Google Scholar
• DeVoss JJ, LeClair NP, Hou Y. An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse. J Immunol 2010;184:4236-46
   PubMed Web of Science ®Google Scholar
• Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 2002;298:1395-401
   PubMed Web of Science ®Google Scholar
• Devoss JJ, Shum AK, Johannes KP, et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol 2008;181:4072-9
   PubMed Web of Science ®Google Scholar
• Zhou D, Chen YT, Chen F, et al. Critical involvement of macrophage infiltration in the development of Sjogren’s syndrome-associated dry eye. Am J Pathol 2012;181:753-60
   PubMed Web of Science ®Google Scholar
• Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 2005;174:1862-70
   PubMed Web of Science ®Google Scholar
• Donate A, Voigt A, Nguyen CQ. The value of animal models to study immunopathology of primary human Sjogren’s syndrome symptoms. Expert Rev Clin Immunol 2014;10(4):469-81
   PubMed Web of Science ®Google Scholar
• Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. ScientificWorldJournal 2011;11:2391-402
   PubMed Web of Science ®Google Scholar
• Baban B, Liu JY, Abdelsayed R, Mozaffari MS. Reciprocal relation between GADD153 and Del-1 in regulation of salivary gland inflammation in Sjogren syndrome. Exp Mol Pathol 2013;95:288-97
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
   PubMed Web of Science ®Google Scholar
• Chen YT, Lazarev S, Bahrami AF, et al. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren’s syndrome. Lab Invest 2012;92:556-70
   PubMed Web of Science ®Google Scholar
• Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren’s syndrome. Am J Pathol 2010;177:1333-43
   PubMed Web of Science ®Google Scholar
• Li S, Gallup M, Chen YT, McNamara NA. Molecular mechanism of proinflammatory cytokine-mediated squamous metaplasia in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2010;51:2466-75
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen FY, Vijmasi T, et al. Pax6 downregulation mediates abnormal lineage commitment of the ocular surface epithelium in aqueous-deficient dry eye disease. PLoS One 2013;8:e77286
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Platts LA, Tuominen S, et al. Role of nitric oxide in Sjogren’s syndrome. Arthritis Rheum 1997;40:875-83
   PubMedGoogle Scholar
• Beauregard C, Brandt PC, Chiou GC. Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-1beta in cultured lacrimal gland acinar cells. Exp Eye Res 2003;77:109-14
   PubMed Web of Science ®Google Scholar
• Vijmasi T, Chen FY, Chen YT, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 2013;19:1957-65
   PubMed Web of Science ®Google Scholar
• Greenwell-Wild T, Moutsopoulos NM, Gliozzi M, et al. Chitinases in the salivary glands and circulation of patients with Sjogren’s syndrome: macrophage harbingers of disease severity. Arthritis Rheum 2011;63:3103-15
   PubMed Web of Science ®Google Scholar
• Gliozzi M, Greenwell-Wild T, Jin W, et al. A link between interferon and augmented plasmin generation in exocrine gland damage in Sjogren’s syndrome. J Autoimmun 2012;40:122-33
   PubMed Web of Science ®Google Scholar
• Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012;92:509-19
   PubMed Web of Science ®Google Scholar
• Li X, Wu K, Edman M, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci 2010;51:5019-29
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjogren’s syndrome: a pilot study. J Rheumatol 2004;31:96-101
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
   PubMed Web of Science ®Google Scholar
• Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009;129:1100-14
   PubMed Web of Science ®Google Scholar
• Solomon S, Rajasekaran N, Jeisy-Walder E, et al. A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. Eur J Immunol 2005;35:3064-73
   PubMed Web of Science ®Google Scholar
• Nikolic T, Geutskens SB, van Rooijen N, et al. Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab Invest 2005;85:487-501
   PubMed Web of Science ®Google Scholar
• Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1412-18
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of mizoribine for the treatment of Sjogren’s syndrome: a multicenter open-label clinical trial. Mod Rheumatol 2007;17:464-9
   PubMed Web of Science ®Google Scholar
• Willeke P, Schluter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. Arthritis Res Ther 2007;9:R115
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome--a double blind, randomised clinical trial. PLoS One 2012;7:e30123
   PubMed Web of Science ®Google Scholar
• Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013;131:715-23
   PubMed Web of Science ®Google Scholar